MD

Business Context and Reporting Period

Company: Pediatrix Medical Group, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: Pediatrix is the nation's largest health care services company focused on physician services for newborn, maternal-fetal, and other pediatric subspecialty care. The company operates a national network of approximately 690 affiliated physicians, including 540 neonatologists, providing care in 30 states and Puerto Rico. Key services include staffing Neonatal Intensive Care Units (NICUs), maternal-fetal medicine, pediatric intensive care, cardiology, and newborn screening (hearing and metabolic).

Key Financial Metrics (Year Ended Dec 31, 2003)

Cash Flow: Net cash provided by operating activities was $118.0 million. Net cash used in investing activities was $90.5 million, primarily due to acquisitions ($75.2 million) and capital expenditures ($15.3 million). Net cash used in financing activities was $72.8 million, driven by $100.0 million in stock repurchases.

Material Changes vs. Prior Period

• Revenue Growth: Net patient service revenue increased 18.4% ($85.7 million). Approximately $30.1 million (35.1%) was attributable to acquisitions and new hospital contracts. Same-unit revenue increased 12.4% due to billing code changes, increased patient days, and modest price increases.
• Profitability: Net income increased 22.5% to $84.3 million. Operating income rose 22.1% to $136.9 million. The operating margin improved by 0.7 percentage points, primarily due to a reduction in general and administrative expenses as a percentage of revenue.
• Expenses: Practice salaries and benefits increased 18.1% to $310.8 million, driven by new physician hires, volume growth, and higher incentive compensation ($54.0 million in 2003 vs. $36.3 million in 2002). General and administrative expenses increased 12.0%, partly due to legal fees associated with government investigations.
• Liquidity: Cash and cash equivalents decreased significantly from $73.2 million to $27.9 million. This reduction was primarily due to the use of cash for stock repurchases ($100 million in 2003), acquisitions ($75.2 million), and the purchase of the corporate office building ($10.1 million).
• Balance Sheet: Goodwill increased by $64.4 million due to the acquisition of seven physician groups and a metabolic screening laboratory. Total liabilities increased, largely due to higher accrued expenses (salaries, bonuses, and professional liability reserves).

Guidance, Outlook, Risks, and Contingencies

Outlook and Strategy: Management plans to invest $50 million to $60 million in cash during 2004 on acquisitions. The company anticipates that funds from operations and current cash on hand will be sufficient to finance working capital, acquisitions, and capital expenditures for the next 12 months.

Government Investigations (Material Contingency):

• FTC Investigation: An active and ongoing investigation by the Federal Trade Commission regarding competition issues related to the 2001 acquisition of Magella and general business practices.
• Medicaid/TRICARE Investigations: Active federal and state investigations into billing practices for Medicaid and TRICARE programs. In November 2003, a search warrant was served on the Las Vegas, Nevada maternal-fetal practice regarding Medicaid billings.
• Impact: Management cannot predict the timing or outcome of these investigations or whether they will have a material adverse effect on the business.

Risk Factors:

• Reimbursement Risk: Significant reliance on government-sponsored programs (Medicaid), which are subject to rate reductions and retroactive adjustments. Government payors accounted for 25% of net patient service revenue in 2003.
• Geographic Concentration: Texas accounted for approximately 31% of net patient service revenue in 2003. Adverse conditions in this market could materially impact results.
• Insurance Costs: Professional liability insurance premiums are expected to increase significantly, and coverage may not be available on favorable terms upon renewal in May 2004.
• Antitrust: Ongoing FTC scrutiny poses a risk of penalties or required divestitures.

Key Facts for Investor Verification

• Investigation Status: Verify the current status and potential financial exposure of the ongoing FTC antitrust investigation and the federal/state Medicaid billing investigations.
• Reimbursement Rates: Monitor changes in Medicaid reimbursement rates and the impact of billing code modifications on net revenue, particularly given the 25% reliance on government payors.
• Insurance Renewal: Confirm the terms and cost of the professional liability insurance renewal scheduled for May 2004, as premiums are expected to rise significantly.
• Geographic Diversification: Assess the company's ability to reduce reliance on the Texas market, which generated 31% of total revenue.
• Acquisition Integration: Evaluate the financial performance and integration of the seven physician groups and the metabolic screening laboratory acquired in 2003.